Non-surgical abortion: who's for methotrexate?
Potts
M
M
School of Public Health, University of California, Berkeley, USA.
D000019:Abortifacient Agents / Q000008:administration & dosage*; D000028:Abortion, Induced; D064420:Drug-Related Side Effects and Adverse Reactions; D035082:Federal Government; D005260:Female; D006076:Government; D033161:Government Regulation; D006805:Human Experimentation; D006801:Humans; D008722:Methods; D008727:Methotrexate / Q000008:administration & dosage*; D015735:Mifepristone / Q000008:administration & dosage; D016595:Misoprostol; D004364:Pharmaceutical Preparations; D010820:Physicians; D011247:Pregnancy; D037841:Pregnant People; D011361:Professional Competence; D012306:Risk; D018570:Risk Assessment; D012926:Social Control, Formal; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration
D000019:Abortifacient Agents; D004364:Pharmaceutical Preparations; D016595:Misoprostol; D015735:Mifepristone; D008727:Methotrexate